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Abstract 24 
Pakistan has a high prevalence of hepatitis C virus (HCV) infection, estimated at 4.9% (2,290/46,843) 25 
in the 2007 national HCV sero-prevalence survey. We used data from this survey to assess the 26 
importance of risk factor associations with HCV prevalence in Pakistan. 27 
Exposures were grouped as community (going to the barbers, sharing smoking equipment, having an 28 
ear/nose piercing, tattoo or acupuncture), healthcare (ever having haemodialysis, blood transfusion, 29 
or ≥5 injections in the last year), demographic (marital status and age), and socio-economic (illiterate 30 
or labourer). We used mutually adjusted multivariable regression analysis, stratified by sex, to 31 
determine associations with HCV infection, their population attributable fraction, and how risk of 32 
infection accumulates with multiple exposures. Strength of associations were assessed using 33 
adjusted odds ratios (aOR). 34 
Community [aOR females 1.5(95% CI 1.2,1.8); males 1.2(1.1,1.4)] and healthcare [females 35 
1.4(1.2,1.6); males 1.2(1.1,1.4)] exposures, low socio-economic status [females 1.6(1.3,1.80); males 36 
1.3(1.2,1.5)], and marriage [females 1.5(1.2,1.9); males 1.4(1.1,1.8)] were associated with increased 37 
HCV infection. Among married women, the number of children was associated with an increase in 38 
HCV infection; linear trend aOR per child 1.06 (1.01,1.11). Fewer infections could be attributed to 39 
healthcare exposures (females 13%; males 6%) than to community exposures (females 25%; males 40 
9%). Prevalence increased from 3% to 10% when cumulative exposures increased from 1 to ≥4 [aOR 41 
per additional exposure for females 1.5(1.4,1.6); males 1.2(1.2,1.3)].    42 
A combination of community, healthcare and other factors appear to drive the Pakistan HCV 43 
epidemic, highlighting the need for a comprehensive array of prevention strategies.   44 
45 
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Introduction 46 
Hepatitis C virus (HCV) infection is a blood-borne pathogen that causes considerable 47 
morbidity and mortality globally1, 2. Recent estimates suggest that there are an estimated 80 million 48 
people living with HCV infection globally3. In developed countries, the primary mode of HCV 49 
transmission is injecting drug use4, 5, but most of the HCV burden is concentrated in lower and 50 
middle income countries1, 2, where most transmission is thought to be due to non-sterile healthcare 51 
and community practices6, 7, 8, 9, 10, 11. Healthcare practices associated with HCV-related risk include 52 
injections for medical purposes, blood transfusion, surgery, dental procedures, and receipt of 53 
intravenous infusions10, 12, 13, 14, 15. Community exposures found to be associated with HCV infection 54 
include barbering, tattooing, and ear and nose piercing9, 12, 16, 17 .     55 
The prevalence of HCV infection in most countries is low (<1%), but exceeds 4% in at least 12 56 
countries including Egypt, Georgia, Nigeria, Russia, and Pakistan3, 13, 18. The burden of HCV is also 57 
concentrated, with about half (over 50 million) of all exposed adults (anti-HCV positive) living in six 58 
countries: Egypt, Pakistan, India, China, Russia and Nigeria3.  59 
Since the World Health Organisation (WHO) released its Global Health Strategy for 60 
eliminating viral hepatitis19, there has been substantial interest in gaining a better understanding of 61 
how much HCV treatment scale-up is needed to reduce the transmission of HCV to low levels, 62 
especially in the highest prevalence settings such as Egypt, Georgia, and Pakistan20 21. However, to 63 
achieve large reductions in HCV transmission, it is also crucial to tackle the underlying risk factors 64 
that drive HCV transmission. Additionally, to effectively scale-up treatment it is also important to 65 
understand how to optimally target HCV testing interventions to minimize costs. This is especially 66 
true for countries with such a large burden of HCV as Pakistan, where there are an estimated 9 67 
million people affected18, and healthcare expenditure only makes up 0.9% of GDP (compared to 68 
10.0% across the EU and 17.1% in USA22). Understanding what risk factors and markers are 69 
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predictive of HCV infection (eg. testing anti-HCV positive on a screening assay) could inform efficient, 70 
targeted screening recommendations that could reduce costs. 71 
Recognised interventions for reducing HCV transmission among people who inject drugs 72 
(PWID) include opiate substitution therapy23, 24, 25, 26, 27 and needle and syringe provision25, 28, whereas 73 
modelling suggests that HCV treatment as prevention may also be an effective intervention29, 30. 74 
Beyond PWID, the focus globally for reducing HCV transmission has centred on behaviour change 75 
strategies (by WHO and the Safe Injection Global Network (SIGN)) to minimise unsafe injections31. 76 
During 2000 to 2010, these strategies succeeded in reducing reuse of injection equipment from 77 
39.6% to 5.5% in the 71 countries assisted by WHO (including Pakistan)32. Recently, WHO launched a 78 
new global policy on injection safety to be piloted in a number of countries33.  79 
In Pakistan, since 2005 a number of major hepatitis prevention and control programs34, 35 80 
have focused on ensuring safe blood transfusions, improving disposal of syringes, increasing public 81 
awareness, and educating healthcare professionals and barbers36, 37, 38; but unfortunately the 82 
effectiveness of these interventions in reducing HCV transmission in Pakistan is unknown. 83 
In 2007, a large (n=46,843) national sero-prevalence survey for HCV was carried out in 84 
Pakistan, and found anti-HCV prevalence of 4.9% overall, 6.7% amongst adults (aged ≥16 years), 85 
which did not differ by sex18. HCV infection prevalence was higher in the more populous provinces of 86 
Punjab (6.7%) and Sindh (5.0%), than in the less populated provinces of North West Frontier (1.5%) 87 
and Baluchistan (1.1%). Previous analyses using this dataset have only considered univariate 88 
associations with HCV sero-prevalence meaning that these associations did not take into account the 89 
effects of other variables and were open to issues of confounding. In this report, we expand on 90 
these previous unadjusted analyses by undertaking a multivariable analysis of associations with 91 
exposures and risk factors for HCV infection. We estimate the population attributable fraction (PAF) 92 
of HCV due to grouped community or healthcare exposures and risk factors. The PAF assesses the 93 
proportion of prevalent infections attributable to different exposures, and depends both on the 94 
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strength of association with HCV infection and the population prevalence of the risk factor. We also 95 
assess the cumulative effect of multiple exposures on lifetime HCV-related risk.  96 
Materials and methods 97 
Data Collection 98 
Survey methods and sampling frame have been described previously18. Briefly, the survey 99 
was conducted in four provinces with households drawn from primary sampling units (PSU), 138 100 
urban and 212 rural. Included subjects gave consent to being tested. 101 
Demographic information 102 
Age, sex, marital status (never married, married, divorced/separated/widowed), and 103 
relationship with the survey responder were collected for all members of the household. Each 104 
person and household had a unique identifier and was labelled with the district and province. If a 105 
person’s age was missing they were removed from the analysis. Age was grouped as 20-29, 30-39, 106 
40-49 and 50-59 years. The district was used to categorise households as urban or rural. 107 
Outcome variable 108 
Sample testing for HCV was carried out using the rapid Advanced Quality One Step HCV Test 109 
(Bionike Inc.) system, which is estimated to have a sensitivity of 97.1% (95% confidence interval: 110 
89.8–99.6%) and specificity of 96.3% (92.5–98.5%)39. Participants were only tested for antibodies to 111 
HCV (anti-HCV), not active infection. 112 
Exposures and risk factors collected in the survey 113 
Data were collected on whether participants had ever received haemodialysis, blood 114 
transfusion, had a history of surgery, had a family history of HCV infection, practised matam (ranges 115 
from ceremonial chest beating to self-flagellation with implements such as chains, and blades)40, 41, 116 
had visited a dentist, had visited a barber, shared a toothbrush, shared smoking equipment, had 117 
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either a tattoo or acupuncture, had either an ear or nose piercing. The number of medical injections 118 
received in the last year (0, 1-4, 5-10, >10), and the type or syringe used (none, new disposable, re-119 
used syringe, don’t know) was recorded. Occupation was dichotomised as labourer or not, education 120 
was dichotomised as illiterate or not.  121 
Derived variables – grouped exposures and risk factors (S-ES, healthcare, and community) 122 
Risk factors and exposures that are surrogates for risk factors (for example, literacy as an 123 
indicator of socio-economic status) were grouped as socio-economic status (S-ES), healthcare risk, 124 
and community risk exposures. S-ES for all individuals was defined using data on the survey 125 
responder (assumed to be the head of the household). An individual was defined to have low S-ES if 126 
the head of the household was either a labourer or illiterate. Risk due to healthcare exposures was 127 
high if the person had previously had haemodialysis, a blood transfusion, or ≥5 injections in the last 128 
year. Lower numbers of yearly injections were not included as a healthcare risk exposure because 129 
77% of the population reported at least 1 injection in the last year. Community exposures included 130 
going to the barber, sharing smoking equipment, having an ear or nose piercing, or having a tattoo 131 
or acupuncture. For each of the healthcare and community grouped risk/exposure variables, we 132 
counted the number of exposures and categorised them as 0, 1, or ≥2 risk factors. We also counted 133 
the total number of exposures (0, 1, 2, 3, 4 or ≥5 risk factors). 134 
We also hypothesised that unsafe childbirth practices could be a risk factor for HCV 135 
acquisition in adult females. Although the survey did not directly ask respondents about their 136 
number of childbirths, it did list each household member and what their relationship was to the 137 
head of the household. Therefore, for females aged 20-59 years that described themselves as wife or 138 
head of household, and who identified themselves as married, the number of childbirths (0, 1, 2, 3, 139 
4, ≥5 children) was estimated by counting the number of children in the household described as sons 140 
or daughters. We did not estimate number of childbirths for older females because of the increased 141 
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likelihood that some of their children will have left home. Age was grouped as 20-29, 30-39, 40-49 142 
and 50-59 years in this analysis. 143 
Statistical analysis 144 
We tabulated HCV prevalence for the country, and by province and district. We also 145 
tabulated prevalence by age (0-19, 20-29, ≥30 years) and sex and cross-tabulated with the 146 
prevalence of risk factors/exposures for HCV acquisition.  147 
Association of exposures and risk factors with HCV  148 
We used logistic regression to estimate the unadjusted and mutually adjusted odds ratio 149 
(OR) (with 95% confidence intervals (CI)) for HCV infection for each exposure. Separate models were 150 
estimated for each age group (0-19, 20-29, ≥30 years) and sex to see how associations varied across 151 
these groups. We also estimated the association of age with HCV prevalence by fitting separate 152 
models for males and females that included age as a covariate. Robust standard errors accounted for 153 
clustering by household. 154 
To assess which of social, healthcare, or community interventions might have more impact 155 
on HCV risk/exposure, we grouped variables into these domains and re-estimated mutually adjusted 156 
sex-specific models which were also adjusted for province, age, and marital status. We performed a 157 
separate analysis splitting the derived group variables into their individual components. We 158 
examined whether age modified the association of exposures with HCV infection by including the 159 
interaction with age as a continuous variable. We defined Population Attributable Fraction (PAF) 160 
(equation 1) as the proportional reduction in HCV that would occur if the risk factor were reduced to 161 
no exposure, and calculated this for each of the three factor domains42. We examined the 162 
relationship between HCV prevalence and the total number of risk factor exposures by fitting sex-163 
specific models adjusted for age and province. Exposures included in this analysis were having >4 164 
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injections, haemodialysis, blood transfusions, going to the barber, ear/nose piercing, 165 
tattoo/acupuncture, sharing smoking equipment, marriage, illiteracy and being a labourer. 166 
Equation 1:   167 
 = current prevalence of exposure (e.g. >4 medical injections) 168 
RR = the adjusted relative risk of disease due to that specific exposure 169 
In a separate analysis we investigated the importance of childbirth for HCV acquisition in 170 
wives aged 20-59 years, adjusting associations for age, province, S-ES, healthcare and community 171 
risk. We did this among married females, as only those who are married were assumed to have 172 
children in Pakistan. 173 
Sensitivity analyses 174 
As the prevalence of HCV was much higher in the more populated provinces (Punjab and 175 
Sindh compared to Baluchistan and North West Frontier), we performed sensitivity analyses (i) 176 
without adjusting for province, (ii) omitting Baluchistan and North-west Frontier provinces.  177 
Analyses were conducted in part through the National Institute for Health Research Unit 178 
(NIHR HPRU) in Evaluation of Interventions (University of Bristol) in partnership with Public Health 179 
England. 180 
Statistical analyses were performed in Stata 13. 181 
 182 
Results 183 
Overall 2,290/46,843 (4.9% [95% CI 4.7-5.1%]) of participants had HCV antibodies. The HCV 184 
prevalence was 4.8% (4.6-5.1%) and 4.9% (4.7-5.2%) for females and males, respectively. The 185 
prevalence of HCV was 6.7% (6.4-7.0%), 5.1% (4.6-5.5%), 1.1% (0.9-1.3%) and 1.5% (1.2-1.8%) in 186 
Punjab, Sindh, Baluchistan and the North-west Frontier, respectively. 187 
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Association of ungrouped exposures and risk factors with HCV  188 
Table 1 summarises the exposures associated with HCV stratified by age categories (0-19, 189 
20-29, ≥30 years) and gender, which can be seen in further detail in supplementary table 1. 190 
Prevalence of exposures and association with HCV infection varied by these different categories, 191 
with HCV infection rates being higher among married persons (both males and females) compared 192 
to never married, increasing with age, and with community and healthcare exposures.  193 
Association of grouped exposures and risk factors with HCV 194 
The HCV prevalence and the unadjusted and adjusted (for age, marital status, province, 195 
community, healthcare, S-ES) OR (95% CI) of HCV infection for the community, healthcare, and S-ES 196 
grouped exposures are shown in table 2, separately for males and females. Community, healthcare 197 
and S-ES exposures were all strongly associated with HCV infection. The increase in adjusted odds of 198 
prevalent HCV infection associated with one community exposure was similar to that associated 199 
with one healthcare exposure. Although the association of HCV infection with multiple healthcare 200 
exposures was much stronger than that due to multiple community factors, only a small proportion 201 
of the population was exposed to multiple healthcare exposures (females 0.8%; males 0.2%). Older 202 
age was associated with HCV infection, with a more than doubling of the rate among males aged ≥40 203 
years compared with those aged 20-29 years. Ever (versus never) being married was also associated 204 
with HCV infection. Results from the sensitivity analyses – both those excluding provinces with very 205 
low prevalence (supplementary table 2) and those not adjusting for province (supplementary table 206 
3) – were similar to the main analysis, which included all provinces and adjusted for province. A 207 
separate analysis where we did not group the exposures that comprised the community, healthcare, 208 
and S-ES variables (supplementary table 4) shows that a high percentage of those who had had 209 
haemodialysis or a blood transfusion had HCV infection but few individuals had undergone these 210 
procedures. 211 
Population attributable fraction of HCV prevalence due to different exposures and risk factors  212 
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Most HCV infections were not attributable to an identified risk factor/exposure, although a 213 
greater proportion of HCV infections among females, 38% compared to 15% of males, were 214 
attributable to either a community or healthcare exposure, with community factors accounting for a 215 
greater proportion of HCV infections among both females and males (figure 1). The PAF suggests 216 
that prevention of exposure to community risks could potentially reduce HCV prevalence by 25% 217 
(95% CI: 13-35%) and 9% (2-16%) in females and males, respectively. In contrast, prevention of 218 
exposure to healthcare risks could potentially reduce HCV prevalence by 13% (8-19%) in females and 219 
6% (2-10%) in males. Among both females and males, a high proportion of HCV appeared to be 220 
attributable to the exposures ever being married (19% and 23%, respectively) and low S-ES (13% and 221 
23%, respectively).  222 
Association of cumulative number of risk factors/exposures with HCV infection 223 
The cumulative number of exposures increased with age, among both females and males 224 
(figure 2). Females accumulated risk factor exposures earlier than males. The prevalence of HCV 225 
infection also increased as the number of exposures increased (figure 3). The HCV prevalence for 226 
individuals with 0, 1, 2, 3, 4 and ≥5 lifetime exposures was 2%, 3%, 5%, 8%, 11% and 15%, 227 
respectively, with the majority of HCV infections (77%) being among individuals with two or more 228 
risk factor exposures. In Punjab and Sindh, the prevalence for individuals with ≥5 exposures was 13% 229 
and 17%, respectively. The aOR of HCV per additional exposure was 1.51 (1.41,1.61) for females and 230 
1.21 (1.15,1.27) for males.  231 
Association of childbirth with HCV infection 232 
There were 5,556 married females aged 20-59 years old. There was an increase in HCV 233 
infection prevalence associated with the number of children; linear trend, aOR per child 1.06 234 
(1.01,1.11). 235 
Discussion 236 
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Main Findings 237 
Our findings identified healthcare associated exposures, including childbirth, as an important 238 
category of risk associated with HCV infection in Pakistan. In addition, our findings also suggest that 239 
various community risk factors/exposures, low socio-economic status (S-ES), and marriage are 240 
associated with increased risk of HCV infection in the country. We estimate that the risk of HCV 241 
infection increases with cumulative lifetime healthcare exposures and accounts for 13% of female 242 
and 6% of male infections, whereas community exposures and low S-ES together account for over 243 
20% and 10% of infections in females and males, respectively. Marriage also emerged as an 244 
important surrogate marker of risk for both sexes, accounting for about 20% of all prevalent 245 
infections; what factors in marriage contribute to HCV infection in Pakistan needs additional study.   246 
Unrecognized/unidentified risk factors beyond those associated with marriage, may also play an 247 
important role in transmission, as demonstrated by the large proportion of infections not 248 
attributable to either community or healthcare exposures identified in this survey. One potential 249 
important contributor could be injection drug use, which is a well-documented risk factor for HCV 250 
transmission, with injecting drug users having a very high prevalence of HCV infection17, 43, 44, 45; 251 
unfortunately this risk factor was not included in the survey. Alternatively, medical injections may be 252 
more important than our analysis suggests; there was a high prevalence in the population, amongst 253 
both HCV exposed and unexposed individuals, limiting the degree to which we could ascertain the 254 
association.   255 
Strengths and limitations 256 
Our study was based on a very large sample size which included children as well as adults. 257 
Our results should be generalizable to the population of Pakistan as data were gathered from 100 258 
districts in four provinces. However, the risk factor/exposure questions were limited in scope, often 259 
asking whether behaviours had ever occurred, which may have limited the degree to which we could 260 
ascribe elevated risk to them.  HCV is a chronic condition, thus, infection could have resulted 261 
throughout the lifetime of the study subject, further limiting the ability to associate recent 262 
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exposures with infection.   We were unable to determine why marriage and low S-ES were 263 
associated with increased prevalence of HCV infection – they may be surrogate markers for risk 264 
factors on which we did not have data, or possibly have an effect on healthcare utilization. We also 265 
lacked direct data on the number of childbirths amongst females, or where, including home or 266 
facility based deliveries, and what type of delivery was performed which limited the scope of our 267 
analyses on this risk factor. The survey did not enquire about female genital mutilation or male 268 
circumcision, both of which result in parenteral exposures.  Our method for measuring the number 269 
of childbirths is likely to underestimate the total number as some children will have died or left 270 
home; however it should still be a useful proxy measure for the number of childbirths that a woman 271 
has had. It is possible that we may have overestimated risk associated with community risk factors, 272 
as accurate attribution of risk to specific medical/healthcare interventions, that are common in the 273 
population, to a chronic infection such as HCV may not reflect the risk of specific exposures. 274 
We used anti-HCV prevalence to determine associations with HCV infection because testing 275 
for current HCV infection (eg PCR testing for presence of HCV RNA) was not performed. Further, we 276 
could not determine acute vs. chronic HCV infection; this is a universal problem; very few studies 277 
have assessed risk factors for recent, acute or incident HCV infections amongst the general 278 
population9, 46, 47, 48. This limits the degree to which we can determine current risk factors for HCV 279 
transmission as individuals with HCV antibody may have been infected in the distant past or more 280 
recently. Importantly, our analysis found similar associations with HCV prevalence in younger and 281 
older individuals suggesting similar risk factors may exist now as in the past. One exception was 282 
medical injections which was only associated with HCV infection among study subjects aged over 30 283 
years. We cannot determine whether this is because cumulative exposure is more important or 284 
there has been a reduction in the risk due to medical injections in recent years.   285 
Comparison with other studies 286 
Risk factors for HCV in Pakistan Trickey: 13 
 
 
 
Our findings are consistent with previous studies examining risk factors for HCV infection15, 287 
16, 43, 45, 49, 50 in Pakistan. In agreement with some studies, we found the importance of healthcare and 288 
community exposures for HCV transmission, including medical injections, childbirth, attending 289 
barbers and ear/nose piercing15, 16, 51, 52, 53, 54, 55, 56, 57. However, not all studies are in agreement, and 290 
some did not find an association with piercing16, 17, 43, 45, 49, 58, barbering or medical injections17, 43, 291 
although these were much smaller surveys. Another study on women in Pakistan found higher S-ES 292 
was associated with a higher proportion of injections received using a new syringe, as opposed to re-293 
use. This is one of the possible explanations of the protective association of S-ES on HCV infection 294 
that we found, and was confirmed in our dataset (results not shown)59 This variable could also be a 295 
marker of accessing better quality health care which could also have a similar effect on reducing HCV 296 
risk. 297 
 As found in other studies in Pakistan and elsewhere9, 12, 60, 61, 62, 63, marriage is associated with 298 
HCV infection for both sexes. The reasons for this are uncertain, with some studies suggesting sexual 299 
HCV transmission or shared use of personal items12, 63. For females in our study, the dominant 300 
exposures included ear and nose piercing, while a separate, restricted analysis also found childbirth 301 
to be an important exposure, possibly due to parenteral exposures64. For almost every female in 302 
Pakistan, ear and nose piercing is a cultural ritual which is undertaken in very early years of life (<5 303 
years)65. Contact with barbers was associated with HCV infection among males. Barbering may be an 304 
important risk exposure among children as well as adults as every child (both male and female) 305 
undergoes head shaving until seven days of age65. Also, all male children undergo circumcision, 306 
which is mostly carried out by barbers in rural areas, but less so in urban areas66.  307 
 Importantly for planning screening interventions, the cumulative number of risk factor 308 
exposures reported by an individual was highly predictive of HCV infection, with the sero-prevalence 309 
of HCV exceeding 10% among individuals with four exposures, and 15% in those with five or more; 310 
the effect was even more pronounced, 13% and 17% respectively, if they were from Punjab or Sindh. 311 
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Implications 312 
Our results highlight the importance of HCV prevention interventions not only targeting 313 
potential healthcare risks/exposures in Pakistan, but also community settings and family behaviours 314 
where exposures may occur. These are likely to include barbering and ear piercing, and family 315 
behaviours such as sharing personal items like razors, toothbrushes, glass sharing, and practices 316 
associated with childbirth16, 45, 49, 52. More research is needed to better understand the main risk 317 
behaviours occurring in different settings. For instance, childbirth may be high risk only in certain 318 
settings, or when specific obstetric or gynaecological procedures are involved50, 52, 67. A recent meta-319 
analysis found that caesarean section conferred a high risk for HCV infection (OR=3.35)11, and other 320 
studies have documented the risk of HCV infection to both mother and child after normal labour12, 68, 321 
69. 322 
A number of educational interventions have been undertaken in Pakistan over the past 323 
decade to tackle community and general36 risk exposures such as barbering, tattooing and body 324 
piercing36, 37, 38, 70. For instance, in 2014/2015, the Health Foundation71 developed an HCV 325 
educational intervention in Karachi, Pakistan, that aimed to educate the general public on healthcare 326 
and community risk factors through health educator volunteers and electronic and print media. A 327 
similar intervention is being done in Azad Kashmir in Northern Pakistan72. There is a need to better 328 
understand the effectiveness and impact of these interventions on practices and HCV transmission.   329 
Conclusions 330 
In summary, our results highlight the multitude of community and health care exposures 331 
that drive HCV transmission in Pakistan; similar risk factors for transmission have been identified 332 
from Egypt8, 9, 11, 12, 73. These findings underscore the urgent need for implementation of strategies to 333 
decrease HCV transmission in Pakistan and other countries with similar risk profiles. Treatment 334 
scale-up for HCV infection, with the new highly effective direct acting antivirals74, 75, is planned in 335 
Pakistan, and many are already receiving treatment76. The finding from our study that HCV infection 336 
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is strongly associated with cumulative number of self-reported risk factors/exposures could help 337 
inform screening strategies to efficiently target individuals at highest risk for HCV infection. While 338 
scaling-up treatment is urgently needed to tackle the huge burden of HCV in Pakistan, policy makers 339 
should also remember the need for large-scale prevention interventions to curtail the continued 340 
transmission of HCV. Indeed, the low prevalence of HCV in many neighbouring countries77, 78 341 
suggests the required changes in behaviour should be possible with suitable interventions, including 342 
education campaigns, to improve knowledge on HCV transmission risks. These education campaigns 343 
need to be tailored to the local situation, which may require further research to identify the reasons 344 
why marriage, childbirth, and S-ES are associated with increased HCV risk in Pakistan.   345 
 346 
347 
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Table 1: Variables significantly associated (p<0.05) with HCV infection, and associated adjusted 
odds ratios (95% confidence interval) of HCV infection, stratified by age category and gender. This 
table summarises supplementary tables 1a, 1b and 1c. 
Males OR (95% CI) Females OR (95% CI) 
Aged 0-19 years: 
Barber (vs not) 1.74 (1.09, 2.78) Tattoo or acupuncture (vs not) 12.4 (3.43, 44.5) 
Ear or nose piercing (vs not) 2.67 (1.45, 4.92) Ear or nose piercing (vs not) 1.61 (1.20, 2.15) 
Labourer (vs not) 1.96 (1.21, 3.15) Illiterate (vs not) 1.62 (1.19, 2.20) 
Family history of HCV (vs not) 2.63 (1.35, 5.15) Re-used syringe (vs none/new) 1.76 (1.18, 2.63) 
Aged 20-29 years: 
Barber (vs not) 1.42 (1.00, 2.00) Married (vs never) 1.58 (1.15, 2.19) 
Ear or nose piercing (vs not) 2.21 (1.00, 4.91) Other marital status (vs never) 3.77 (1.07, 13.3) 
Labourer (vs not) 1.76 (1.19, 2.60) Barber (vs not) 4.22 (1.01, 17.6) 
Family history HCV (vs not) 2.73 (1.42, 5.25) Tattoo or acupuncture (vs not) 3.37 (1.04, 11.0) 
  
Ear or nose piercing (vs not) 2.30 (1.40, 3.76) 
  
Family history of HCV (vs not)  1.95 (1.09, 3.50) 
  
Blood transfusion (vs never) 5.69 (1.71, 19.0) 
Aged ≥30 years: 
Married (vs never) 1.60 (1.16, 2.22) Illiterate (vs not) 1.43 (1.15, 1.78) 
Barber (vs not) 1.45 (1.24, 1.70) Labourer (vs not) 2.04 (1.29, 3.20) 
Illiterate (vs not) 1.30 (1.11, 1.52) 5-10 injections (vs 0) 1.64 (1.16, 2.31) 
Labourer (vs not) 1.40 (1.18, 1.67) >10 injections (vs 0) 1.91 (1.31, 2.77) 
<5 injections (vs 0) 1.71 (1.31, 2.24) Re-used syringe (vs none/new) 0.64 (0.51, 0.81) 
5-10 injections (vs 0) 1.67 (1.25, 2.24) Family history of HCV (vs not) 2.57 (1.87, 3.53) 
>10 injections (vs 0) 2.40 (1.71, 3.37) Haemodialysis (vs never) 4.37 (1.61, 11.9) 
Re-used syringe (vs none/new) 0.54 (0.44, 0.66) Blood transfusion (vs never) 2.49 (1.55, 3.99) 
Unknown syringe type (vs 
none/new) 
0.42 (0.29, 0.61) 
  
Family history of HCV (vs not) 1.91 (1.38, 2.64) 
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Table 2: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted odds ratio (95% CI) of HCV infection by sex. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  
  Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.43 (1.14, 1.78)  p=0.002 9,811 8% 3.53 (3.07, 4.06)  1.54 (1.23, 1.94)  p<0.001 
Community risks 0 17,306 3% 1 1   6,796 3% 1 1   
Community risks 1 6,105 9% 2.73 (2.41, 3.10)  1.22 (1.06, 1.41)  p=0.006 15,492 6% 2.18 (1.85, 2.58)  1.46 (1.21, 1.76)  p<0.001 
Community risks ≥2 914 12% 4.10 (3.30, 5.10)  1.34 (1.06, 1.69)  p=0.013 230 10% 3.82 (2.41, 6.07)  2.07 (1.25, 3.44)  p=0.005 
S-ES risks 0 14,166 4% 1 1  10,389 3% 1 1  
S-ES risks ≥1 10,159 7% 1.84 (1.64, 2.07)  1.33 (1.17, 1.51)  p<0.001 12,129 6% 2.00 (1.75, 2.30)  1.55 (1.33, 1.81)  p<0.001 
Healthcare risks 0 17,570 4% 1 1   15,660 4% 1 1   
Healthcare risks 1 6,701 6% 1.45 (1.28, 1.65)  1.21 (1.06, 1.39)  p=0.005 6,675 7% 1.75 (1.54, 1.99)  1.40 (1.22, 1.61)  p<0.001 
Healthcare risks ≥2 54 20% 5.57 (2.86, 10.83)  3.31 (1.69, 6.47)  p<0.001 183 22% 7.16 (5.00, 10.26)  4.17 (2.84, 6.14)  p<0.001 
Punjab (Province) 13,186 7% 1 1 
 
11,926 7% 1 1 
 
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.69 (0.59, 0.82)  p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.67 (0.56, 0.79)  p<0.001 
Baluchistan 3,831 1% 0.15 (0.11, 0.22)  0.16 (0.11, 0.22)  p<0.001 3,766 1% 0.16 (0.11, 0.22)  0.14 (0.10, 0.19)  p<0.001 
North West Frontier 2,668 1% 0.18 (0.13, 0.27)  0.19 (0.13, 0.28)  p<0.001 2,605 2% 0.24 (0.17, 0.33)  0.20 (0.14, 0.29)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.48 (0.35, 0.66) p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.63 (0.46, 0.85)  p=0.003 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.77 (0.60, 0.99) p=0.041 5,808 2% 0.48 (0.38, 0.60)  0.69 (0.53, 0.89) p=0.005 
Age 20-29 4,420 4% 1 1 
 
4,272 5% 1 1 
 
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.53 (1.20, 1.95)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.47 (1.20, 1.81)  p<0.001 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.43 (1.90, 3.09)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.40 (1.12, 1.75)  p=0.003 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.41 (1.85, 3.14)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.55 (1.21, 1.98)  p<0.001 
Age 60+ 1,634 11% 3.06 (2.47, 3.79)  2.22 (1.71, 2.88)  p<0.001 1,117 9% 1.90 (1.48, 2.43)  1.25 (0.96, 1.63)  p=0.10 
S-ES: socio-economic status
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FIGURE LEGENDS 
 
FIGURE 1: Population attributable fraction of HCV infection due to community and healthcare risks. 
 
FIGURE 2: Proportion of the population experiencing different numbers of exposures for HCV infection by age and sex. 
Exposures included in this analysis were having >4 injections, haemodialysis, blood transfusions, going to the barber, ear/nose 
piercing, tattoo/acupuncture, sharing smoking equipment, marriage, illiteracy and being a labourer. 
 
FIGURE 3: Proportion of population, HCV prevalence, and proportion of infections among individuals with different numbers of 
exposures. 
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Supplementary table 1: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted odds ratio (95% CI) of HCV infection by 
age and sex. 
Supplementary table 1a: Males and females aged 0-19 years 
 Males Aged 0-19  Females aged 0-19 
 HCV OR (95% CI) P 
value 
  HCV OR (95% CI)    P 
value Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 11518 (99) 220 (1.9) 1 1   10415 (96) 219 (2.1) 1 1  
  Married 129 (1.1) 4 (3.1) 1.64 (0.60,4.51) 1.15 (0.44,3.00) 0.78  392 (3.6) 12 (3.1) 1.47 (0.82,2.65) 1.11 (0.61,2.02) 0.74 
  other 22 (0.2) 1 (4.5) 2.45 (0.32,18.4) 2.17 (0.26,18.1) 0.47  14 (0.1) 0 (0) NA NA  
Urban (v. rural) 4463 (38) 80 (1.8) 0.89 (0.66,1.19) 0.91 (0.67,1.25) 0.56  4360 (40) 79 (1.8) 0.77 (0.55,1.06) 0.85 (0.58,1.22) 0.37 
Community risk            
Barber 587 (5.2) 24 (3.9) 2.21 (1.44,3.40) 1.74 (1.09,2.78) 0.02  22 (0.2) 0 (0) NA NA  
Sharing smoking eqpt. 49 (0.4) 1 (2.0) 1.06 (0.15,7.73) 0.60 (0.09,4.11) 0.60  15 (0.1) 0 (0) NA NA  
Sharing a toothbrush 86 (0.7) 2 (2.3) 1.21 (0.30,4.90) 1.21 (0.31,4.79) 0.78  75 (0.7) 2 (2.7) 1.26 (0.30,5.30) 1.15 (0.27,4.85) 0.85 
Tattoo or acupuncture 24 (0.2) 0 NA NA   11 (0.1) 3 (27) 17.4 (4.38,69.2) 12.4 (3.43,44.5) <0.001 
Ear or nose piercing 268 (2.3) 13 (4.9) 2.69 (1.47,4.91) 2.67 (1.45,4.92) 0.002  6151 (57) 155 (2.5) 1.56 (1.17,2.08) 1.61 (1.20,2.15) 0.001 
Matam 23 (0.2) 1 (4.3) 2.32 (0.37,14.7) 1.31 (0.18,9.52) 0.79  8 (0.1) 0 (0)  NA  
Socio-economic status           
Illiterate 3809 (33) 78 (2.1) 1.10 (0.83,1.46) 1.03 (0.76,1.39) 0.85  4406 (41) 122 (2.8) 1.65 (1.24,2.20) 1.62 (1.19,2.20) 0.002 
Labourer 575 (4.9) 25 (4.4) 2.48 (1.61,3.80) 1.96 (1.21,3.15) 0.006  175 (1.6) 2 (1.1) 0.53 (0.13,2.10) 0.42 (0.10,1.69) 0.22 
Healthcare risk            
No. of injections (v. 0) 3447 (30) 61 (1.8) 1 1   2996 (28) 59 (2.0)  1  
  <5 injections 5934 (51) 108 (1.8) 1.03 (0.73,1.44) 0.88 (0.62,1.26) 0.49  5617 (52) 130 (2.3) 1.18 (0.84,1.65) 0.92 (0.65,1.29) 0.61 
  5-10 injections 1905 (16) 48 (2.5) 1.43 (0.95,2.16) 1.03 (0.65,1.63) 0.89  1838 (17) 37 (2.0) 1.02 (0.67,1.55) 0.69 (0.44,1.08) 0.10 
  >10 injections 383 (3.3) 8 (2.1) 1.18 (0.56,2.50) 0.89 (0.41,1.94) 0.768  370 (3.4) 5 (1.4) 0.68 (0.27,1.70) 0.50 (0.20,1.29) 0.15 
Syringe use (v. none/new) 9826 (84) 173 (1.8) 1 1   9118 (84) 176 (1.9) 1 1  
  Re-used syringe 1201 (10) 37 (3.1) 1.76 (1.14,2.74) 1.50 (0.99,2.28) 0.056  1096 (10) 37 (3.4) 1.74 (1.13,2.67) 1.76 (1.18,2.63) 0.006 
  Unknown syringe type 642 (5.5) 15 (2.3) 1.33 (0.72,2.44) 1.29 (0.71,2.34) 0.40  607 (5.6) 18 (3.0) 1.52 (0.64,3.60) 1.47 (0.62,3.50) 0.38 
Dentist 31 (0.3) 0 NA NA   44 (0.4) 2 (4.6) 2.19 (0.52,9.22) 2.47 (0.58,10.5) 0.22 
Family history HCV 205 (1.8) 10 (4.9) 2.68 (1.36,5.29) 2.63 (1.35,5.15) 0.005  213 (2.0) 4 (1.9) 0.88 (0.32,2.36) 0.93 (0.34,2.55) 0.89 
Haemodialysis 10 (0.1) 0 NA NA   13 (0.1) 0 (0) NA NA  
Blood transfusion 16 (0.1) 0 NA NA   19 (0.2) 2 (11) 5.43 (1.24,23.73) 11.5 (0.96,138) 0.054 
History of surgery 132 (1.1) 1 (0.8) 0.38 (0.05,2.73) 0.35 (0.05,2.62) 0.31  104 (1.0) 3 (2.9) 1.37 (0.43,4.33) 0.59 (0.08,4.36) 0.60 
TOTAL 11669 (100) 225 (1.9)     10821 (100) 213 (2.0)    
NA – not applicable – no cases of HCV infection 
 
Risk factors for HCV in Pakistan Trickey: 26 
 
 
 
Supplementary table 1b: Males and females aged 20-29 years 
 Males Aged 20-29  Females aged 20-29 
 HCV OR (95% CI) P 
value 
  HCV OR (95% CI) P value 
Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 3121 (71) 108 (3.5) 1 1   1870 (44) 63 (3.4) 1 1  
  Married 1284 (29) 64 (5.0) 1.45 (1.05,1.99) 1.31 (0.94,1.82) 0.11  2373 (56) 138 (5.8) 1.77 (1.31,2.40) 1.58 (1.15,2.19) 0.005 
  Other 15 (0.3) 0 (0) NA NA   29 (0.7) 3 (10) 3.31 (0.98,11.2) 3.77 (1.07,13.3) 0.039 
Urban (v. rural) 1897 (43) 69 (3.6) 0.89 (0.64,1.22) 0.89 (0.64,1.23) 0.47  1799 (42) 77 (4.3) 0.83 (0.62,1.11) 0.85 (0.61,1.17) 0.31 
Community risk            
Barber 1823 (41) 90 (4.9) 1.59 (1.17,2.17) 1.42 (1.00,2.00) 0.047  26 (0.6) 3 (12) 2.62 (0.78,8.87) 4.22 (1.01,17.6) 0.048 
Sharing smoking eqpt. 217 (4.9) 12 (5.5) 1.48 (0.82,2.67) 1.12 (0.60,2.10) 0.72  37 (0.9) 4 (11) 2.44 (0.85,7.02) 1.45 (0.47,4.55) 0.52 
Sharing a toothbrush 72 (1.6) 5 (6.9) 1.87 (0.77,4.51) 1.57 (0.62,3.97) 0.34  29 (0.7) 2 (6.9) 1.48 (0.33,6.58) 1.61 (0.36,7.12) 0.53 
Tattoo or acupuncture 47 (1.1) 3 (6.4) 1.70 (0.53,5.46) 1.18 (0.36,3.88) 0.78  24 (0.6) 4 (17) 4.05 (1.35,12.17) 3.37 (1.04,11.0) 0.043 
Ear or nose piercing 111 (2.5) 8 (7.2) 1.94 (0.93,4.07) 2.21 (1.00,4.91) 0.051  3349 (78) 181 (5.4) 2.23 (1.44,3.46) 2.30 (1.40,3.76) <0.001 
Matam 14 (0.3) 1 (7.1) 1.91 (0.33,11.0) 1.92 (0.36,10.1) 0.44  6 (0.1) 0 (0) NA NA  
Socio-economic status           
Illiterate 1168 (26) 47 (4.0) 1.05 (0.74,1.48) 0.93 (0.64,1.35) 0.72  2129 (50) 111 (5.2) 1.21 (0.91,1.61) 0.99 (0.71,1.38) 0.91 
Labourer 817 (19) 51 (6.2) 1.92 (1.35,2.72) 1.76 (1.19,2.60) 0.005  88 (2.1) 5 (5.7) 1.21 (0.48,3.03) 1.14 (0.45,2.88) 0.78 
Healthcare risk            
No. of injections (v. 0) 1049 (24) 35 (3.3) 1 1   798 (19) 31 (3.9) 1 1  
  <5 injections 2032 (46) 80 (3.9) 1.19 (0.79,1.79) 1.13 (0.64,1.99) 0.68  2043 (48) 82 (4.0) 1.03 (0.67,1.60) 0.79 (0.43,1.45) 0.45 
  5-10 injections 1090 (25) 42 (3.9) 1.16 (0.73,1.86) 1.06 (0.57,1.99) 0.85  1122 (26) 68 (6.1) 1.60 (1.02,2.49) 1.11 (0.58,2.14) 0.75 
  >10 injections 249 (5.6) 15 (6.0) 1.86 (0.98,3.53) 2.03 (0.92,4.48) 0.08  309 (7.2) 23 (7.4) 1.99 (1.13,3.51) 1.43 (0.67,3.02) 0.36 
Syringe use (v. none/new) 1600 (36) 62 (3.9) 1 1   1341 (31) 57 (4.3) 1 1  
  Re-used syringe 2559 (58) 103 (4.0) 1.22 (0.82,1.81) 0.91 (0.57,1.46) 0.7  2656 (62) 131 (4.9) 1.28 (0.85,1.94) 0.96 (0.59,1.56) 0.87 
  Unknown syringe type 261 (5.9) 7 (2.7) 0.80 (0.32,1.98) 0.52 (0.20,1.36) 0.18  275 (6.4) 16 (5.8) 1.53 (0.80,2.92) 1.11 (0.54,2.29) 0.78 
Dentist 49 (1.1) 0 (0) NA NA   52 (1.2) 2 (3.9) 0.80 (0.19,3.30) 0.75 (0.17,3.30) 0.70 
Family history HCV 132 (3.0) 14 (10) 3.10 (1.63,5.92) 2.73 (1.42,5.25) 0.003  163 (3.8) 16 (9.8) 2.27 (1.30,3.97) 1.95 (1.09,3.50) 0.025 
Haemodialysis 6 (0.1) 1 (17) 4.96 (0.58,42.7) 7.77 (0.98,61.6) 0.052  6 (0.1) 1 (16.7) 4.00 (0.47,34.44) 2.36 (0.14,38.8) 0.55 
Blood transfusion 9 (0.2) 0 (0) NA NA   56 (1.3) 8 (14) 3.42 (1.60,7.31) 5.69 (1.71,19.0) 0.005 
History of surgery 151 (3.4) 2 (1.3) 0.32 (0.08,1.32) 0.27 (0.06,1.16) 0.078  185 (4.3) 11 (6.0) 1.28 (0.68,2.38) 0.44 (0.16,1.25) 0.13 
TOTAL 4420 (100) 172 (3.9)     4272 (100) 204 (4.8)    
NA – not applicable – no cases of HCV infection 
 
 
 
Risk factors for HCV in Pakistan Trickey: 27 
 
 
 
Supplementary table 1c: Males and females aged ≥30 years 
 Males aged ≥ 30 years  Females aged ≥ 30 years 
 HCV OR (95% CI) P value   HCV OR (95% CI) P value 
Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 654 (7.9) 39 (6.0) 1 1   422 (5.6) 23 (5.5)    
  Married 7310 (89) 739 (10) 1.77 (1.28,2.44) 1.60 (1.16,2.22) 0.004  6317 (85) 569 (9.0) 1.70 (1.11,2.61) 1.52 (0.98,2.34) 0.060 
  Other 272 (3.3) 27 (9.9) 1.73 (1.05,2.85) 1.43 (0.85,2.38) 0.18  686 (9.3) 61 (8.9) 1.68 (1.02,2.76) 1.41 (0.85,2.35) 0.19 
Urban (v. rural) 3257 (40) 330 (10) 1.07 (0.92,1.24) 1.17 (0.99,1.37) 0.060  3039 (41) 255 (8.4) 0.92 (0.77,1.09) 0.96 (0.79,1.16) 0.67 
Community risk            
Barber 3580 (44) 441 (12) 1.66 (1.43,1.92) 1.45 (1.24,1.70) <0.001  49 (0.7) 4 (8.2) 0.92 (0.33,2.57) 1.00 (0.35,2.84) 1 
Sharing smoking eqpt. 991 (12) 132 (13) 1.50 (1.23,1.83) 1.23 (0.99,1.54) 0.061  126 (1.7) 10 (7.9) 0.89 (0.46,1.72) 0.72 (0.37,1.40) 0.33 
Sharing a toothbrush 161 (2.0) 22 (14) 1.46 (0.93,2.29) 1.29 (0.79,2.09) 0.31  62 (0.8) 8 (13) NA NA  
Tattoo or acupuncture 78 (1.0) 8 (10) 1.06 (0.51,2.20) 0.87 (0.40,1.89) 0.73  46 (0.6) 1 (2.2) 0.23 (0.03,1.68) 0.20 (0.03,1.55) 0.12 
Ear or nose piercing 159 (1.9) 14 (8.8) 0.89 (0.51,1.54) 1.01 (0.58,1.76) 0.98  6087 (82) 562 (9.2) 1.39 (1.09,1.77) 1.28 (0.98,1.66) 0.067 
Matam 36 (0.4) 2 (5.6) 0.54 (0.13,2.30) 0.41 (0.09,1.80) 0.24  10 (0.1) 2 (20) NA NA  
Socio-economic status           
Illiterate 3765 (46) 410 (11) 1.26 (1.09,1.46) 1.30 (1.11,1.52) 0.001  5494 (74) 518 (9.4) 1.38 (1.13,1.69) 1.43 (1.15,1.78) 0.001 
Labourer 1736 (21) 232 (13) 1.59 (1.35,1.88) 1.40 (1.18,1.67) <0.001  145 (2.0) 25 (17) 2.20 (1.43,3.41) 2.04 (1.29,3.20) 0.002 
Healthcare risk            
No. of injections (v. 0) 1536 (19) 130 (8.4) 1 1   1081 (15) 83 (7.8) 1 1  
  <5 injections 3649 (44) 362 (9.9) 1.19 (0.97,1.47) 1.71 (1.31,2.24) <0.001  3275 (44) 244 (7.5) 0.95 (0.73,1.24) 1.22 (0.88,1.69) 0.24 
  5-10 injections 2280 (28) 221 (9.7) 1.16 (0.93,1.46) 1.67 (1.25,2.24) <0.001  2222 (30) 224 (10) 1.33 (1.02,1.73) 1.64 (1.16,2.31) 0.005 
  >10 injections 771 (9.4) 92 (12) 1.47 (1.10,1.95) 2.40 (1.71,3.37) <0.001  847 (11) 101 (12) 1.60 (1.18,2.19) 1.91 (1.31,2.77) <0.001 
Syringe use (v. 
none/new) 
2532 (31) 290 (11) 1 
1  
 2002 (27) 191 (9.6) 1 1  
  Re-used syringe 51784 (63) 475 (9.2) 1.09 (0.89,1.34) 0.54 (0.44,0.66) <0.001  4937 (66) 415 (8.4) 1.09 (0.85,1.40) 0.64 (0.51,0.81) <0.001 
  Unknown syringe type 520 (6.3) 40 (7.7) 0.90 (0.62,1.30) 0.42 (0.29,0.61) <0.001  486 (6.6) 46 (9.5) 1.24 (0.85,1.81) 0.75 (0.52,1.10) 0.15 
Dentist 245 (3.0) 30 (12) 1.30 (0.88,1.92) 1.14 (0.76,1.69) 0.53  270 (3.6) 29 (10.7) NA NA  
Family history HCV 296 (3.6) 53 (18) 2.08 (1.53,2.84) 1.91 (1.38,2.64) <0.001  280 (3.8) 60 (21) 3.01 (2.22,4.08) 2.57 (1.87,3.53) <0.001 
Haemodialysis 12 (0.2) 2 (17) 1.68 (0.37,7.59) 1.75 (0.39,7.86) 0.46  18 (0.2) 6 (33) 5.22 (1.95,13.9) 4.37 (1.61,11.9) 0.004 
Blood transfusion 77 (0.9) 12 (16) 1.71 (0.92,3.19) 1.95 (0.95,4.00) 0.069  222 (3.0) 47 (21) 2.92 (2.09,4.08) 2.49 (1.55,3.99) <0.001 
History of surgery 594 (7.2) 56 (9.4) 0.96 (0.72,1.27) 0.83 (0.60,1.15) 0.27  673 (9.1) 86 (13) 1.60 (1.25,2.03) 0.99 (0.70,1.40) 0.95 
TOTAL 8236 (100) 805 (9.8)     7425 (100) 653 (8.8)    
NA – not applicable – no cases of HCV infection 
Risk factors for HCV in Pakistan Trickey: 28 
 
 
 
Supplementary Table 2: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted odds ratio (95% CI) of HCV infection by 
sex, with the Baluchistan and North West Frontier provinces omitted. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  
  Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Never married 11,175 3% 1 1   9,267 3% 1 1   
Ever married 6,651 12% 4.22 (3.70, 4.82)  1.47 (1.17, 1.86)  p=0.001 6,880 10% 3.67 (3.17, 4.25)  1.57 (1.23, 2.01)  p<0.001 
Community risks 0 11,858 4% 1 1   5,076 3% 1 1   
Community risks 1 5,138 10% 2.45 (2.15, 2.80)  1.27 (1.10, 1.48)  p=0.002 10,948 7% 2.25 (1.90, 2.67)  1.44 (1.18, 1.75)  p<0.001 
Community risks ≥2 830 13% 3.50 (2.80, 4.37)  1.43 (1.13, 1.81)  p=0.003 123 15% 5.15 (3.07, 8.63)  2.22 (1.27, 3.87)  p=0.005 
S-ES risks 0 10,206 5% 1 1  8,002 4% 1 1  
S-ES risks ≥1 7,620 8% 1.74 (1.54, 1.97) 1.28 (1.12, 1.46)  p<0.001 8,145 8% 2.21 (1.91, 2.55)  1.52 (1.30, 1.78)  p<0.001 
Healthcare risks 0 13,165 6% 1 1   11,409 5% 1 1   
Healthcare risks 1 4,619 8% 1.50 (1.31, 1.72)  1.18 (1.02, 1.36)  p=0.024 4,584 9% 1.82 (1.58, 2.09)  1.39 (1.21, 1.61)  p<0.001 
Healthcare risks ≥2 42 26% 5.99 (3.00, 11.96)  3.54 (1.76, 7.14)  p<0.001 154 25% 6.27 (4.28, 9.17)  4.05 (2.71, 6.07)  p<0.001 
Punjab (Province) 13,186 7% 1 1 
 
11,926 7% 1 1 
 
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.70 (0.59, 0.82)  p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.67 (0.56, 0.79)  p<0.001 
Age 0-9 3,737 2% 0.40 (0.30, 0.54)  0.53 (0.38, 0.72) p<0.001 3,587 3% 0.41 (0.32, 0.54)  0.67 (0.49, 0.92)  p=0.012 
Age 10-19 4,641 3% 0.61 (0.48, 0.77)  0.79 (0.61, 1.02) p=0.076 4,175 3% 0.48 (0.38, 0.61)  0.70 (0.53, 0.92) p=0.010 
Age 20-29 3,350 5% 1 1 
 
3,079 6% 1 1 
 
Age 30-39 2,121 9% 1.98 (1.59, 2.47)  1.55 (1.21, 2.00)  p<0.001 2,055 11% 1.89 (1.54, 2.31)  1.46 (1.17, 1.81)  P=0.001 
Age 40-49 1,706 14% 3.38 (2.74, 4.16)  2.45 (1.90, 3.15)  p<0.001 1,477 12% 2.03 (1.64, 2.52)  1.45 (1.15, 1.83)  p=0.002 
Age 50-59 1,058 15% 3.40 (2.69, 4.29)  2.48 (1.88, 3.26)  p<0.001 925 13% 2.24 (1.76, 2.86)  1.54 (1.19, 1.99)  P=0.001 
Age 60+ 1,213 13% 3.03 (2.42, 3.80)  2.09 (1.59, 2.75)  p<0.001 849 11% 1.95 (1.50, 2.52)  1.31 (1.00, 1.73)  p=0.053 
S-ES: socio-economic status
Risk factors for HCV in Pakistan Trickey: 29 
 
 
 
Supplementary Table 3: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted odds ratio (95% CI) of HCV infection by 
sex, without adjustment for province. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  
  Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.34 (1.07, 1.67)  p=0.010 9,811 8% 3.53 (3.07, 4.06)  1.46 (1.17, 1.83)  p<0.001 
Community risks 0 17,306 3% 1 1   6,796 3% 1 1   
Community risks 1 6,105 9% 2.73 (2.41, 3.10)  1.63 (1.42, 1.87)  P<0.001 15,492 6% 2.18 (1.85, 2.58)  1.45 (1.21, 1.73)  p<0.001 
Community risks ≥2 914 12% 4.10 (3.30, 5.10) 1.89 (1.50, 2.38)  P<0.001 230 10% 3.82 (2.41, 6.07)  1.62 (0.99, 2.63)  p=0.052 
S-ES risks 0 14,166 4% 1 1  10,389 3% 1 1  
S-ES risks ≥1 10,159 7% 1.84 (1.64, 2.07)  1.35 (1.19, 1.53)  p<0.001 12,129 6% 2.00 (1.75, 2.30)  1.35 (1.16, 1.57)  p<0.001 
Healthcare risks 0 17,570 4% 1 1   15,660 4% 1 1   
Healthcare risks 1 6,701 6% 1.45 (1.28, 1.65)  1.02 (0.89, 1.17)  p=0.75 6,675 7% 1.75 (1.54, 1.99)  1.26 (1.10, 1.44)  p<0.001 
Healthcare risks ≥2 54 20% 5.57 (2.86, 10.83)  2.69 (1.37, 5.28)  P=0.004 183 22% 7.16 (5.00, 10.26)  3.96 (2.72, 5.76)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.50 (0.37, 0.69) p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.60 (0.45, 0.82)  p<0.001 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.80 (0.63, 1.03) p=0.087 5,808 2% 0.48 (0.38, 0.60)  0.65 (0.51, 0.85) p<0.001 
Age 20-29 4,420 4% 1 1 
 
4,272 5% 1 1 
 
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.54 (1.21, 1.95)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.51 (1.23, 1.85)  p<0.001 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.41 (1.90, 3.07)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.46 (1.17, 1.81)  P<0.001 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.35 (1.81, 3.06)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.66 (1.31, 2.11)  p<0.001 
Age 60+ 1,634 11% 3.06 (2.47, 3.79)  2.28 (1.76, 2.95)  p<0.001 1,117 9% 1.90 (1.48, 2.43)  1.44 (1.11, 1.87)  p=0.006 
S-ES: socio-economic status
Risk factors for HCV in Pakistan Trickey: 30 
 
 
 
Supplementary Table 4: Prevalence of individual risk factors/exposures and HCV infection, unadjusted and mutually adjusted odds ratio (95% CI) of HCV 
infection by sex. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  
  Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Freq. 
HCV 
Prev. 
Unadjusted Adjusted 
Adj. p-
value 
Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.42 (1.14, 1.78)  p=0.002 9,811 8% 3.53 (3.07, 4.06)  1.52 (1.21, 1.92)  p<0.001 
Barber 6,014 9% 2.78 (2.46, 3.13) 1.18 (1.03, 1.35) P=0.020 97 7% 1.54 (0.71, 3.33) 1.46 (0.66, 3.24) p=0.36 
Ear or nose piercing 539 6% 1.35 (0.93, 1.95)  1.58 (1.07, 2.33)  p=0.022 15,603 6% 2.18 (1.85, 2.56) 1.49 (1.23, 1.79)  p<0.001 
Tattoo/acupuncture 149 7% 1.54 (0.83, 2.85)  1.04 (0.56, 1.94)  p=0.91 81 10% 2.17 (1.07, 4.38) 2.42 (1.12, 5.25)  p=0.025 
Sharing smoking eqpt. 1,257 12% 2.72 (2.26, 3.27) 1.13 (0.93, 1.38) P=0.22 178 8% 1.69 (0.97, 2.95) 1.00 (0.57, 1.75) p=0.99 
Illiterate 8,744 6% 1.46 (1.29, 1.64) 1.15 (1.01, 1.31) p=0.038 12,029 6% 2.01 (1.75, 2.30) 1.57 (1.35, 1.83) p<0.001 
Labourer 3,128 10% 2.48 (2.16, 2.85) 1.25 (1.07, 1.46)  p=0.004 408 8% 1.70 (1.19, 2.42)  1.30 (0.90, 1.88)  p=0.16 
>4 Medical Injections 6,678 6% 1.48 (1.30, 1.68) 1.24 (1.08, 1.42) p=0.002 6,708 7% 1.77 (1.55, 2.01) 1.37 (1.19, 1.57) p<0.001 
Haemodialysis 29 10% 2.22 (0.67, 7.36)  2.01 (0.59, 6.80) P=0.26 37 19% 4.62 (2.06, 10.4)  3.20 (1.38, 7.39) p=0.007 
Blood transfusion 102 12% 2.58 (1.41, 4.73)  1.52 (0.82, 2.82) P=0.18 297 19% 4.88 (3.61, 6.60) 2.90 (2.10, 4.00)  p<0.001 
Punjab (Province) 13,186 7% 1 1 
 
11,926 7% 1 1 
 
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.69 (0.58, 0.81)  p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.65 (0.55, 0.77)  p<0.001 
Baluchistan 3,831 1% 0.15 (0.11, 0.22)  0.16 (0.11, 0.23)  p<0.001 3,766 1% 0.16 (0.11, 0.22)  0.14 (0.10, 0.19)  p<0.001 
North West Frontier 2,668 1% 0.18 (0.13, 0.27)  0.20 (0.14, 0.28)  p<0.001 2,605 2% 0.24 (0.17, 0.33)  0.20 (0.14, 0.28)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.49 (0.36, 0.67) p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.63 (0.46, 0.85)  p=0.003 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.76 (0.59, 0.97) p=0.028 5,808 2% 0.48 (0.38, 0.60)  0.69 (0.53, 0.89) p=0.004 
Age 20-29 4,420 4% 1 1 
 
4,272 5% 1 1 
 
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.55 (1.22, 1.97)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.47 (1.19, 1.81)  p=0.003 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.45 (1.92, 3.12)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.39 (1.11, 1.74)  p=0.004 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.45 (1.88, 3.18)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.55 (1.21, 1.98)  p<0.001 
Age 60+ 1,634 11% 3.06 (2.47, 3.79)  2.29 (1.76, 2.98)  p<0.001 1,117 9% 1.90 (1.48, 2.43)  1.25 (0.96, 1.63)  p=0.10 
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Supplementary material 1: Survey questionnaire, household. 
 
Supplementary material 2: Survey questionnaire, individual. 
 
